Rocket Pharmaceuticals, INC

Rocket Pharmaceuticals announced strong Q2 2026 results, highlighted by the FDA approval of KRESLADI, a $180 million capital infusion from its sale, and positive initial safety data for its Danon disease gene therapy.

Rocket Pharmaceuticals announced a positive clinical safety update for its RP-A501 gene therapy in Danon disease, with initial patients showing good tolerance and no major adverse events.

Rocket Pharmaceuticals, Inc. has announced the resignation of its VP of Finance, Senior Controller, Treasurer, and Principal Accounting Officer, John Militello, effective July 7, 2026, and the appointment of Joseph Manhede as the new Principal Accounting Officer, effective July 8, 2026.

Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in non-dilutive capital.

Rocket Pharmaceuticals held its 2026 Annual Meeting of Stockholders, with a strong majority approving the election of directors, ratification of its accounting firm, executive compensation, and a stock option exchange program.

Rocket Pharmaceuticals announced first-quarter 2026 financial results, highlighting progress in clinical trials and the monetization of a Priority Review Voucher, extending their operational runway into Q2 2028.

Rocket Pharmaceuticals reports a significant financial boost from a $180 million Priority Review Voucher sale and FDA accelerated approval for its KRESLADI gene therapy, while advancing its cardiovascular pipeline.

Rocket Pharmaceuticals reports a reduced net loss in Q3 2025, driven by strategic restructuring and pipeline prioritization, despite clinical setbacks for RP-A501 and ongoing legal challenges.

Rocket Pharmaceuticals announced a strategic reorganization to prioritize its AAV-based cardiovascular gene therapy platform, reducing its workforce by 30% and extending its cash runway into Q2 2027, despite a clinical hold on its Danon disease trial.

Rocket Pharmaceuticals reports a net loss of $61.33 million for Q1 2025, with R&D expenses decreasing and G&A expenses increasing, while advancing its gene therapy programs.

Rocket Pharmaceuticals reported its Q3 2024 financial results and provided updates on its gene therapy programs, including a CRL for its LAD-I BLA and progress in other clinical trials.

Rocket Pharmaceuticals reported its second quarter 2024 financial results and provided updates on its clinical programs, including a Complete Response Letter from the FDA for its LAD-I program.

Rocket Pharmaceuticals announced a strategic corporate reorganization to focus on its AAV cardiovascular gene therapy platform, de-prioritizing other programs, and successfully resubmitted its Biologics License Application for KRESLADI.

Rocket Pharmaceuticals details its financial performance for 2024 and outlines key advancements in its gene therapy programs.

Rocket Pharmaceuticals' 10-K filing highlights progress in its gene therapy pipeline, including regulatory submissions and clinical trial advancements, while acknowledging financial and operational risks.

Gaurav Shah, CEO of Rocket Pharmaceuticals, Inc., sold 2,837 shares of common stock on August 13, 2026 for $3.38 per share.

Martin Wilson, General Counsel of Rocket Pharmaceuticals, Inc., sold 3,493 shares of common stock on August 13, 2026 for $3.38 per share.

Sarbani Chaudhuri, See Remarks of Rocket Pharmaceuticals, Inc., sold 4,701 shares of common stock on August 11, 2026 for $3.50 per share.

Christopher James Stevens, Chief Operating Officer of Rocket Pharmaceuticals, Inc., reported multiple transactions in common stock on August 3, 2026.

David P Southwell, a Director of Rocket Pharmaceuticals, Inc., reported a transaction in 150,000 shares of common stock on August 3, 2026.

Roderick Wong, a Director and 10% Owner of Rocket Pharmaceuticals, reported transactions involving common stock and stock options.

Rocket Pharmaceuticals announces its 2026 Annual Meeting, seeking approval for director elections, auditor ratification, executive compensation, and a stock option exchange program.

Rocket Pharmaceuticals has filed a definitive proxy statement with the SEC.

Rocket Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to vote on director elections, ratification of the accounting firm, and executive compensation.

Rocket Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Rocket Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on key proposals including the election of directors and an increase in authorized common stock.

Vanguard Portfolio Management has reported a beneficial ownership of 5.35% in Rocket Pharmaceuticals Inc. common stock as of June 30, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Rocket Pharmaceuticals Inc. following an internal realignment.

Maverick Capital, Ltd. and its affiliates reported a 2.3% beneficial ownership stake in Rocket Pharmaceuticals, Inc. as of December 31, 2025.

The Vanguard Group reported a 7.89% beneficial ownership stake in Rocket Pharmaceuticals Inc. as of December 31, 2025, alongside an internal realignment affecting future reporting.

Maverick Capital and its affiliates have disclosed a passive beneficial ownership of 7.8% in Rocket Pharmaceuticals, Inc., totaling 8,363,813 shares.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 0.93% in Rocket Pharmaceuticals, Inc.